ASCO 2026 Annual Meeting Opens in Chicago (May 29-June 2) — Peptide and Targeted-Conjugate Oncology Slate Moves From Abstracts to Podium
The ASCO 2026 Annual Meeting opened today at McCormick Place Chicago, running through June 2, with more than 7,000 abstracts. The peptide-and-targeted-conjugate oncology cohort — pre-released in the May 21 abstract drop and the May 26 embargoed press briefing — now moves to live presentation. Friday May 29 brought the Corbus CRB-701 Nectin-4 ADC cervical/OPSCC data and the Dana-Farber/Bristol multiple myeloma and Pfizer lung cancer readouts. The peptide-mechanism slate across the meeting: Bicycle Therapeutics zelenectide pevedotin Duravelo-2 (bicyclic peptide-MMAE conjugate, oral June 1); Avacta AVA6000 FAP-Dox; BriaCell Bria-IMT cell-and-peptide immunotherapy; Sapience lucicebtide C/EBPβ antagonist (GBM); Aktis AKY-2519 B7-H3 miniprotein radioconjugate; Mayo TPIV200 folate-receptor peptide vaccine (TNBC, June 1); Telix ProstACT PSMA radioligand (June 1); plus the GLP-1 cancer slate (Abstract 3143, Roswell Park breast cancer). The targeted-conjugate categories — Nectin-4, PSMA, B7-H3, FAP, SSTR2 — are the densest peptide-adjacent oncology competition at the meeting.